Leukemia, lymphoma and myeloma, taken together, represent the fifth most commonly occurring cancers and the second leading cause of cancer death. Symptoms of the disease are varied, with some forms of the disease being aggressive and others benign. The discovery of new targeted therapies, advances in chemotherapy and the development of new combination drugs, along with important emerging research have contributed to the significant progress made within the field of hematologic oncology in recent years.
International Journal of Hematologic Oncology is dedicated to presenting the latest and most promising progresses and discoveries in the study of hematologic malignancies and its related fields. The journal provides a forum for the discussion and analysis of emerging advancements in diagnosis, treatment strategies and novel targeted therapies, with an added focus on the overall management of hematologic malignancies and evaluation of prospects for further development.
Discover more peer-reviewed journal content here.